within Pharmacolibrary.Drugs.ATC.L;

model L01FX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.14 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10000 / 1000000,
    adminCount     = 1,
    Vd             = 0.00329,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sacituzumab govitecan is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting Trop-2, linked to the cytotoxic agent SN-38, an active metabolite of irinotecan. It is used for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It is FDA and EMA approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of sacituzumab govitecan (the antibody-drug conjugate, not unconjugated SN-38) in patients with advanced solid tumors as reported in adult females and non-small cell lung cancer patients after intravenous administration.</p><h4>References</h4><ol><li><p>Bardia, A, et al., &amp; Ocean, AJ (2021). Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 32(6) 746–756. DOI:<a href=&quot;https://doi.org/10.1016/j.annonc.2021.03.005&quot;>10.1016/j.annonc.2021.03.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33741442/&quot;>https://pubmed.ncbi.nlm.nih.gov/33741442</a></p></li><li><p>Sathe, AG, et al., &amp; Othman, AA (2024). Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. <i>Clinical pharmacokinetics</i> 63(5) 669–681. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01366-3&quot;>10.1007/s40262-024-01366-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38578394/&quot;>https://pubmed.ncbi.nlm.nih.gov/38578394</a></p></li><li><p>Sathe, AG, et al., &amp; Othman, AA (2025). Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. <i>Clinical pharmacology and therapeutics</i> 117(2) 570–578. DOI:<a href=&quot;https://doi.org/10.1002/cpt.3495&quot;>10.1002/cpt.3495</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39543869/&quot;>https://pubmed.ncbi.nlm.nih.gov/39543869</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX17;
